Unlocking Value and Delivering Shareholder Returns with Holdings in Growth Sectors Worldwide
For over 25 years, DSS, Inc. (NYSE American: DSS) has protected corporations, financial institutions, and governments from sophisticated and costly fraud. In 2019, we began a major transformation.
Today, we take ownership positions or fully acquire businesses in five high-growth sectors to monetize our holdings by:
Our Strategy delivers shareholder value by:
UPDATED AUGUST 7TH, 2023
DSS shareholders of record on that date will be entitled to four (4) shares of Impact Biomedical Inc. for every one (1) share of DSS.
Impact Biomedical shares are registered under CUSIP Number 45259L 106. Shares will not be eligible for resale until 180 days from the date Impact BioMedical’s initial public offering (IPO) becomes effective under the Securities Act, subject to the Company’s discretion to lift the restriction at an earlier date.
Shares should be reflected in your investment account holding your DSS shares already, although the company is aware of some delays with certain firms.
Shareholders are encouraged to contact their respective investment brokers if their accounts do not reflect the distribution yet.
DSS, Inc. is a multinational company operating business segments in product packaging, biotechnology, consumer, commercial lending, securities and investment management, alternative trading, digital transformation, secure living, and alternative energy. Its business model is based on a distribution sharing system in which shareholders receive shares in its subsidiaries as DSS strategically unlocks value through IPO spin-offs. Under new leadership, DSS has built the necessary foundation for sustainable growth through the acquisition and formation of a diversified portfolio of companies positioned to drive profitability in five high-growth sectors. These companies offer innovative, flexible, and real-world solutions that not only meet customer needs but create sustainable value and opportunities for transformation.
See the 05/15/2023 10-Q found here: https://dssworld.com/investor
139,017,172 shares are outstanding (as of 11/17/2022)
57,455,583 shares in the public float (as of 11/17/2022)
~31.3% (as of 11/17/2022)
Impact Biomedical Inc.
American Medical REIT Inc.
American Pacific Bancorp
S-1 is filed. Offering planned for late 2023, contingent on market conditions.
Shareholders will receive 4 shares of Impact Biomedical for each DSS share held except for related parties.
Impact Biomedical has a broad portfolio of technologies and products that range from development to commercial stage. Examples of products closer to commercialization include probiotics and air purification. For more information Impact Biomedical’s pipelines can be viewed here: https://www.impactbiomedinc.com/pipeline/
Currently, Product Packaging, Commercial Banking, and Direct Sales business lines.
Product Packaging: $11,876,000
Commercial Lending: $644,000
View our investor presentation report for additional information on DSS, Inc.